A potent Bcl-2 inhibitor, venetoclax, has been approved by the FDA to treat patients with 17p deletions in chronic lymphocytic leukemia (CLL) (Merino et al., 2018; Roberts et al., 2021). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.